RCT of metformin combinations to maintain weight loss after GLP-1 medication cessation, results not yet reported
This is a randomized controlled trial protocol comparing four groups (control, metformin alone, metformin plus rapamycin, and metformin plus naltrexone) in patients discontinuing GLP-1 receptor agonists. The study aims to assess whether these interventions reduce weight regain over six months post-cessation and improve metabolic markers. No results have been reported; this appears to be a study design document rather than outcome data.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 30, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 6 months
- Population
- Patients weaning off GLP-1 medications who have achieved weight loss
- Primary outcome
- Percentage of weight regain six months after cessation of GLP-1 therapy
- Effect size
- —
- Significance
- Not reported
- Journal
- AgelessRx
- Published
- Jul 30, 2025
Sources
Primary source
- AgelessRx ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.